Heyu Biological Technology Corporation
HYBTOTCHealthcare
$0.35
$-0.25(-41.67%)
Market Cap$361364506
P/E Ratio—
52W High$3.4
52W Low$0.002
Heyu Biological Technology Corporation (HYBT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HYBT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.87M | $2.68M | $0.08M | $0.10M | $0.22M |
| Cost of Revenue | $2.69M | $2.61M | $0.03M | $0.03M | $0.12M |
| Gross Profit | $0.18M | $0.07M | $0.05M | $0.07M | $0.10M |
| Gross Margin %(computed) | 6.34% | 2.59% | 65.31% | 68.58% | 46.78% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.56M | $0.54M | $0.32M | $0.00M | $0.38M |
| Total Operating Expenses | $0.56M | $0.54M | $0.32M | $0.23M | $0.38M |
| Operating Income | ($0.38M) | ($0.47M) | ($0.27M) | ($0.16M) | ($0.28M) |
| Operating Margin %(computed) | -13.16% | -17.56% | -336.63% | -168.78% | -125.28% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.03M | $0.03M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($0.49M) | ($0.45M) | ($0.27M) | ($0.16M) | ($0.75M) |
| Income Tax Expense | ($0.02M) | $0.07M | ($0.00M) | $0.00M | ($0.20M) |
| Net Income | ($0.47M) | ($0.38M) | ($0.27M) | ($0.16M) | ($0.55M) |
| Net Margin %(computed) | -16.46% | -14.16% | -336.12% | -168.97% | -246.07% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 |
| Wtd Avg Shares | 518.83M | 450.23M | 103.25M | 103.25M | 103.25M |
| EBITDA | ($0.38M) | ($0.47M) | ($0.27M) | ($0.16M) | $0.20M |
| EBITDA Margin %(computed) | -13.15% | -17.56% | -336.63% | -168.78% | 87.79% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Heyu Biological Technology Corporation data
About Heyu Biological Technology Corporation (HYBT) Income Statement
Heyu Biological Technology Corporation (HYBT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, HYBT reported revenue of $0.00B, gross profit of $0.00B (gross margin 6.34%), and net income of ($0.00B) — a net profit margin of -16.46%.
Frequently asked questions
HYBT · 4 questionsHeyu Biological Technology Corporation (HYBT) reported revenue of $0.00B for 2024, up 7.1% year-over-year.
HYBT revenueHYBT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08